Your browser doesn't support javascript.
loading
Eficácia do sotalol nas arritmias ventriculares idiopáticas com origem em trato de saída de ventrículo direito / Efficacy of Sotalol in Patients With Idiophatic Right Ventricular Arrhythmias
Maia, Ivan G; Seixas, Tamer N; Costa, Angela Molina; Peres, Ayrton K; Magalhäes Júnior, Abel; Sá, Roberto; Alves, Paulo A. G.
  • Maia, Ivan G; s.af
  • Seixas, Tamer N; s.af
  • Costa, Angela Molina; s.af
  • Peres, Ayrton K; s.af
  • Magalhäes Júnior, Abel; s.af
  • Sá, Roberto; s.af
  • Alves, Paulo A. G; s.af
Arq. bras. cardiol ; 63(1): 59-63, jul. 1994. tab, graf
Article in Portuguese | LILACS | ID: lil-155542
RESUMO
PURPOSE--To evaluate the effects of sotalol in patients (pts) with idiophatic ventricular arrhythmias (VT) from right ventricular outflow tract. METHODS--Eighteen pts with VT were enrolled (five with monomorphic repetitive ventricular tachycardia - MRVT). Pts were submitted to a double-blind crossover randomized study (placebo vs. 320 mg/po/d/sotalol; four weeks each), after a wash-out control period. Holter recording were recorded in control and placebo and drug periods. Eligible pts have > 50/h isolated ventricular premature beats (VPB) in control, with or without paired VPB or nonsustained VT (NSVT- > 3 beats, > 100bpm). Drug efficacy criteria was > 75//reduction in isolated VPB and > 90//of paired VPB or NSVT. The effects of the drug on uncorrected QT interval was evaluated and also on circadian rhythm of VT through the hourly pNN50/VPB ratios. Values are given as mean +/- SD. Three recordings were compared by using paired Student's ®t® test. Statistical significance was assumed for p < 0.05. RESULTS--Differences between control and placebo were NS. Drug was effective in 61//of pts, reducing the 3 types of ET (VPB placebo = 23.508 +/- 34.537; drug 975 +/- 1357; paired placebo = 443 +/- 587; drug = 9 +/- 20). The drug was evaluated in 4 pts with MRVT, reducing all ectopic events, with efficacy of 60//over VPB and paired and 80//over NSVT (VPB placebo = 52.639 +/- 42.207; drug 1631 +/- 2062; paired placebo = 796 +/- 754; drug 20 +/- 30; NSVT placebo = 4287 +/- 6343; drug 9 +/- 11). Mean QT interval was 0.40 +/- 0.01s in control and 0.50 +/- 0.04s in the drug period, with no correlation between duration and efficacy. Sotalol modified the circardian rhythm of VPB in the non-responders group, mainly during the morning. CONCLUSION--Sotalol was effective in control of VT, mainly the MRVT. Its effect on VPB circadian rhythm may independently contribute to the overall efficacy profile and myocardial protective effect of this drug
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Sotalol / Tachycardia, Ventricular Type of study: Controlled clinical trial Limits: Adult / Female / Humans / Male Language: Portuguese Journal: Arq. bras. cardiol Journal subject: Cardiology Year: 1994 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Sotalol / Tachycardia, Ventricular Type of study: Controlled clinical trial Limits: Adult / Female / Humans / Male Language: Portuguese Journal: Arq. bras. cardiol Journal subject: Cardiology Year: 1994 Type: Article